- About Us
- Nano-Social Network
- Nano Consulting
- My Account
* Scientist of international reputation
* Former Head of Oncology Research at Novartis
* "Curiox establishes itself"
Prof. Dr. Alex Matter has joined the Board of Directors of Singaporean Nanostart holding Curiox Biosystems. Dr. Matter is best known for his contribution to the development of Glivec/Gleevec®, one of the world's first tyrosine kinase inhibitor drugs against chronic myeloid leukemia (CML). Starting in the mid-eighties, Dr. Matter led a team of close to 200 scientists at Novartis to discover and optimize the lead compound and brought it all the way through its first clinical trial in 1998. In a short span of 3 years, Glivec/Gleevec® was given a very rare, fast track FDA approval in 2001.
He was the founding director of the Novartis Institute for Tropical Diseases and is Chief Executive Officer of the Experimental Therapeutics Centre (ETC), both located in Singapore. During his long career in the pharmaceutical industry Dr. Matter has held several positions of responsibility such as Head of Pharmaceutical Research at Hoffman-LaRoche, Head of Cancer and Viral Research at CIBA-GEIGY and more recently Global Head of Oncology Research, at Novartis Pharmaceuticals Corporation. Dr. Alex Matter, received his medical degree from the University of Basel. He has authored over 100 scientific articles and book chapters in the areas of oncology and hematology. He is the recipient of the 13th Warren-Alpert prize in 2000 and the AACR-Bruce F. Cain Memorial Award.
Matter comments his service in the Board of Directors of Curiox: "I am looking forward to work with Curiox which pursues innovative, cutting-edge technologies in the field of high throughput screening and establishes itself in a rapidly growing hightech market segment."
Namyong Kim, CEO of Curiox, believes that Matter´s huge experience and network will assure the success of new DropArray™ products that are going to be launched in the next few months for the pharmaceutical and biotech market. Kim says: "The ready acceptance of the invitation by Dr. Matter in joining the Board shows the strength and promise of Curiox's unique DropArray™ technology in innovating the ways of preclinical drug discovery are performed. I look forward to working with him in building Curiox into one of major bioinstrumentation companies."
About Nanostart AG
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
About Curiox Biosystems Pte. Ltd.
Curiox Biosystems has a vision to accelerate the progress of life sciences and drug discovery through better miniaturization. Curiox is a bioinstrumentation company enabling the miniaturization of heterogeneous bioassay for researchers working in life sciences, drug discovery, and diagnostics. Curiox’s patented miniaturization platform, DropArray™, provides up to 1,000 times savings in sample and reagent consumption, and up to 10 times reduction in assay time. The company is located at Biopolis in Singapore, the biomedical hub of Singapore and Southeast Asia. The company is a spin-off from Institute of Bioengineering and Nanotechnology (IBN) backed primarily by Nanostart and Exploit Technologies, the commercializing arm of Singapore’s Agency for Science, Technology and Research (A*STAR). For further information, please visit www.curiox.com.
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the “Entry Standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan.
For more information, please click here
Dr. Hans Joachim Dürr
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © Nanostart AGIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Explaining how 2-D materials break at the atomic level January 20th, 2017
New active filaments mimic biology to transport nano-cargo: A new design for a fully biocompatible motility engine transports colloidal particles faster than diffusion with active filaments January 11th, 2017